General Drug Manufacturers industry stocks
21 companies in the General Drug Manufacturers industry. 15 have a published intrinsic value and 5 trade at least 20% below it.
The median company in General Drug Manufacturers with a published value trades 11% above our estimate of intrinsic value.
Values as of the 22 Sept 2026 close.
Most undervalued stocks in General Drug Manufacturers
Liquid names only: at least $1M traded a day and $50M of market value.
Largest companies in General Drug Manufacturers
- Lilly(Eli) & Co (LLY): overvalued, -35% margin of safety
- Johnson & Johnson (JNJ): overvalued, -32% margin of safety
- Abbvie Inc (ABBV): overvalued, -148% margin of safety
- Merck & Co Inc (MRK): overvalued, -205% margin of safety
- Astrazeneca plc (AZN): slightly undervalued, +7% margin of safety
- Novartis AG ADR (NVS): overvalued, -27% margin of safety
- AMGEN Inc (AMGN): slightly overvalued, -11% margin of safety
- Gilead Sciences Inc (GILD): overvalued, -37% margin of safety
- Pfizer Inc (PFE): undervalued, +49% margin of safety
- Novo Nordisk ADR (NVO): undervalued, +71% margin of safety
- Bristol-Myers Squibb Co (BMY): slightly undervalued, +19% margin of safety
- GSK Plc ADR (GSK): undervalued, +21% margin of safety
- Sanofi ADR (SNY): undervalued, +45% margin of safety
- Biogen Inc (BIIB): overvalued, -54% margin of safety
- Organon & Co (OGN): undervalued, +55% margin of safety
- Grifols SA ADR (GRFS): no reliable verdict
- Amarin Corp ADR (AMRN): not valued
- Nasus Pharma Ltd (NSRX): no published value
- Mira Pharmaceuticals Inc (MIRA): no published value
- Scilex Holding Company (SCLX): not valued
- Medicus Pharma Ltd (MDCX): no published value
Other Healthcare industries
All industries